Premium
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alfero... AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19. Show more
Safety Committee approval based on positive Phase 1 safety data demonstrating the combination therapy to be generally well-tolerated with no severe treatment-related adverse events or...
OCALA, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the final Clinical Study Results for the “Study to Evaluate...
Recently published article on study findings underscores links between study participants infected with SARS-CoV-2 and the incidence of ME/CFS The early-onset broad-spectrum antiviral effect of...
– Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer and Long-COVID spaces –...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0501 | -24.4390243902 | 0.205 | 0.2115 | 0.1408 | 501761 | 0.19030679 | CS |
| 4 | -0.0851 | -35.4583333333 | 0.24 | 0.24 | 0.1408 | 575880 | 0.20550175 | CS |
| 12 | -0.0851 | -35.4583333333 | 0.24 | 0.2726 | 0.1408 | 671177 | 0.21093332 | CS |
| 26 | -0.1701 | -52.3384615385 | 0.325 | 0.3995 | 0.1408 | 455611 | 0.23797445 | CS |
| 52 | -0.2941 | -65.5011135857 | 0.449 | 0.62 | 0.1408 | 353389 | 0.30225819 | CS |
| 156 | -0.6451 | -80.6375 | 0.8 | 1.38 | 0.1408 | 247906 | 0.54476313 | CS |
| 260 | -0.9151 | -85.523364486 | 1.07 | 8.75 | 0.1408 | 1326669 | 2.51880427 | CS |
| Symbole | Prix | Vol. |
|---|---|---|
| OGENOragenics Inc | US$ 0,295 (3,84%) | 247,9M |
| SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 27,70 (5,52%) | 70,43M |
| DNNDenison Mines Corp | US$ 1,855 (0,27%) | 50,88M |
| SPXSDirexion Daily S&P 500 Bear 3X Shares New | US$ 5,775 (-0,94%) | 50,31M |
| NVDQT Rex 2X Inverse NVIDIA Daily Target ETF | US$ 3,255 (-10,45%) | 49,39M |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
